Preventing postnatal type 2 diabetes with metformin (OMAhA Feasibility Trial)


This study compares metformin versus placebo  for 1 year after delivery to prevent type 2 diabetes in women diagnosed with gestational diabetes in pregnancy. The aim of this study is to evaluate the study process, examine the acceptability of the intervention to mothers, and identify reasons for non-participation, non-adherence and withdrawal from the study. The study will also obtain preliminary estimates of the effects of metformin in preventing type 2 diabetes to inform a larger trial.

The Research Partnership Team is supporting the study by providing health economic analysis for the feasibility trial and assisting with patient and public involvement.

Full study title: Effectiveness and acceptability of metformin in preventing the onset of type 2 diabetes after gestational diabetes in postnatal women: A feasibility study for a randomised, blinded placebo-controlled trial

Principal Investigator: Shakila Thangaratinam, Queen Mary University London

Start date and duration: March 2018 to July 2020

Partners and collaborators involved: Bart’s Research Centre for Women’s Health (BARC); Queen Mary University of London